Novartis’ LUTATHERA (lutetium Lu 177 dotatate) has already been a breakthrough in treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). With its approval now extended to pediatric patients, Novartis further strengthens its leadership in oncology. While the lutathera cost remains a central discussion point, this expansion underscores the therapy’s value in addressing...

DelveInsight releases an in-depth cerebral amyloid angiopathy (CAA) market analysis for the 7MM through 2034. The report highlights the absence of approved therapies, Alnylam Pharmaceuticals’ Mivelsiran pipeline asset, the impact of aging populations, and the significant disease burden, with 46% of mild-to-severe cases in Western populations and notable gender disparities. Cerebral...

The JAK Inhibitors Market has evolved into a transformational healthcare sector, fueled by deepening scientific comprehension of JAK–STAT signaling pathways in immune system orchestration and inflammatory response control. As research initiatives continuously identify new therapeutic applications for JAK pathway intervention, key industry players including pharmaceutical corporations,...

For over a decade, Jakafi for myelofibrosis has retained its position as the premier therapeutic solution. As the groundbreaking JAK inhibitor to secure FDA endorsement, Jakafi has continuously delivered exceptional clinical results in symptom management and spleen reduction, establishing itself as a cornerstone treatment option. Its enduring strength within the primary myelofibrosis treatment...